
mRNA cancer vaccine shows 42% reduction in death and recurrence
Hacker News·3w·Moderna, Merck
Moderna and Merck's personalized mRNA cancer vaccine demonstrated a 42% reduction in death and recurrence for melanoma patients in clinical trials. While this is biotech rather than software, it signals how mRNA technology—once dismissed as speculative—is moving into mainstream medical practice, creating downstream opportunities for indie developers building tools in genomics, clinical data management, and personalized medicine workflows.
Original story
Read the original on Hacker NewsRelated stories
